1. Home
  2. MTC vs IFRX Comparison

MTC vs IFRX Comparison

Compare MTC & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MTC

MMTec Inc.

HOLD

Current Price

$3.45

Market Cap

71.8M

Sector

Technology

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.12

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTC
IFRX
Founded
2015
2007
Country
Hong Kong
Germany
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.8M
71.1M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
MTC
IFRX
Price
$3.45
$1.12
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
153.5K
748.5K
Earning Date
12-12-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,675,833.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,075.42
P/E Ratio
N/A
N/A
Revenue Growth
114.77
N/A
52 Week Low
$0.25
$0.71
52 Week High
$3.89
$2.77

Technical Indicators

Market Signals
Indicator
MTC
IFRX
Relative Strength Index (RSI) 68.71 48.91
Support Level $2.76 $0.96
Resistance Level $3.62 $1.16
Average True Range (ATR) 0.32 0.07
MACD 0.03 0.02
Stochastic Oscillator 88.23 77.74

Price Performance

Historical Comparison
MTC
IFRX

About MTC MMTec Inc.

MMTEC Inc provides Internet-based technology services and solutions to the Chinese language speaking hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms engaging in securities market transactions and settlements globally. It offers complete suite trading solutions, including services such as fund establishment, issuance, custody, transaction, and settlement. The Company currently has two operating segments, Gujia, MM Future, HC Securities, and MM Global. It generates maximum revenue from the Gujia segment. Gujia segment provides market data services and investor relations management services to customers in China.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: